Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
MMWR Morb Mortal Wkly Rep. 2000 Dec 22;49(50):1138-40.

Availability and use of parenteral quinidine gluconate for severe or complicated malaria.

Abstract

Since 1991, quinidine gluconate, a class 1a anti-arrhythmic agent, has been the only parenteral antimalarial available for use in the United States (1). It is indicated for the treatment of patients with life-threatening Plasmodium falciparum malaria (2), including those who cannot tolerate oral therapy, have high-grade parasitemia, or have complications (e.g., cerebral malaria or acute renal failure).

PMID:
11190119
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for CDC - Morbidity and Mortality Weekly Report
    Loading ...
    Write to the Help Desk